AAV vectors: The Rubik's cube of human gene therapy

A Pupo, A Fernández, SH Low, A François… - Molecular Therapy, 2022 - cell.com
Defective genes account for∼ 80% of the total of more than 7,000 diseases known to date.
Gene therapy brings the promise of a one-time treatment option that will fix the errors in …

Gene therapy leaves a vicious cycle

R Goswami, G Subramanian, L Silayeva… - Frontiers in …, 2019 - frontiersin.org
The human genetic code encrypted in thousands of genes holds the secret for synthesis of
proteins that drive all biological processes necessary for normal life and death. Though the …

Inherited retinal diseases: Therapeutics, clinical trials and end points—A review

M Georgiou, K Fu**ami… - Clinical & Experimental …, 2021 - Wiley Online Library
Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous group of
disorders characterised by photoreceptor degeneration or dysfunction. These disorders …

Clinical perspective: treating RPE65-associated retinal dystrophy

AM Maguire, J Bennett, EM Aleman, BP Leroy… - Molecular Therapy, 2021 - cell.com
Until recently, there was no approved treatment for a retinal degenerative disease.
Subretinal injection of a recombinant adeno-associated virus (AAV) delivering the normal …

Inherited retinal degenerations: current landscape and knowledge gaps

JL Duncan, EA Pierce, AM Laster… - … vision science & …, 2018 - tvst.arvojournals.org
Inherited retinal degenerations (IRDs) represent a diverse group of progressive, visually
debilitating diseases that can lead to blindness in which mutations in genes that are critical …

[HTML][HTML] Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives

AV Garafalo, AV Cideciyan, E Héon, R Sheplock… - Progress in retinal and …, 2020 - Elsevier
Due to improved phenoty** and genetic characterization, the field of 'incurable'and
'blinding'inherited retinal diseases (IRDs) has moved substantially forward. Decades of …

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia

K Xue, JK Jolly, AR Barnard, A Rudenko, AP Salvetti… - Nature medicine, 2018 - nature.com
Retinal gene therapy is increasingly recognized as a novel molecular intervention that has
huge potential in treating common causes of blindness, the majority of which have a genetic …

Gene therapy for inherited retinal diseases: progress and possibilities

ML Hu, TL Edwards, F O'Hare, DG Hickey… - Clinical and …, 2021 - Taylor & Francis
Inherited retinal diseases (IRDs) comprise a heterogeneous group of genetic disorders
affecting the retina. Caused by mutations in over 300 genes, IRDs result in visual impairment …

[HTML][HTML] Assessment of the electronic retinal implant alpha AMS in restoring vision to blind patients with end-stage retinitis pigmentosa

TL Edwards, CL Cottriall, K Xue, MP Simunovic… - Ophthalmology, 2018 - Elsevier
Purpose To report the initial efficacy results of the Retina Implant Alpha AMS (Retina Implant
AG, Reutlingen, Germany) for partial restoration of vision in end-stage retinitis pigmentosa …

Splice-modulating oligonucleotide QR-110 restores CEP290 mRNA and function in human c. 2991+ 1655A> G LCA10 models

K Dulla, M Aguila, A Lane, K Jovanovic… - … Therapy-Nucleic Acids, 2018 - cell.com
Leber congenital amaurosis type 10 (LCA10) is a severe inherited retinal dystrophy
associated with mutations in CEP290. The deep intronic c. 2991+ 1655A> G mutation in …